New 'Smarter' GLP-1 drug enters first human tests for blood sugar control
NCT ID NCT07327281
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called TQF3250 in 66 healthy adults with high blood sugar. The drug is designed to activate only certain parts of the GLP-1 receptor, aiming for better blood sugar control with fewer side effects. The main goal is to check safety and how the body handles the drug, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TQF3250 capsule (biased GLP-1 receptor agonist)
- What this could lead to
- If successful, this could lead to a new treatment option for high blood sugar with fewer side effects than current GLP-1 drugs.
- What could go wrong
- This is a very early Phase 1 trial in only 66 healthy people, so it is too soon to know if it works or is safe. Side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERGLYCEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Drum Tower Hospital Affiliated to Nanjing University School of Medicine
RECRUITINGNanjing, Jiangsu, 210008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a breath test replace finger pricks for diabetes?
- Could a wearable sensor replace fingerstick checks for sepsis patients in the ICU?
- Could a simple sugar help people with type 1 diabetes exercise safely?
- New diabetes program helps hill tribe elders control blood sugar
- Your personality might predict your lab results
- Gene link to ICU blood sugar problems found